Efgartigimod as Add‐On Treatment in Refractory Guillain–Barré Syndrome: A Case Report
European Journal of Neurology · 2025-08 · 32 (8)
DOI: 10.1111/ene.70308 ↗Kurz gefasst
Fallbericht in der Zeitschrift European Journal of Neurology, online erschienen am 13.08.2025. Verfasst von P Ripellino und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Neurocenter of Southern Switzerland EOC, Ospedale Regionale di Lugano, Lugano, Switzerland. Hauptthemen laut MEDLINE: Guillain-Barre Syndrome, Antibodies, Monoclonal. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 6 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Fondazione Balli.
Abstract (Originalsprache)
Background and Aims Guillain–Barré Syndrome (GBS) is an autoimmune disease that can cause flaccid tetraplegia. Efgartigimod, a monoclonal antibody that inhibits the neonatal receptor (FcRn), increases IgG degradation.
Methods
A 60‐year‐old lady was admitted with acute flaccid tetraparesis, requiring mechanical ventilation within 12 h. Nerve conduction studies were compatible with acute inflammatory demyelinating polyneuropathy (AIDP). No anti‐ganglioside or anti‐nodal/paranodal antibody could be identified in serum. Despite receiving standard treatment with plasma exchange (PLEX), the patient remained severely tetraparetic, bedridden, and mechanically ventilated. Human immunoglobulin 2 g/kg was given, without obtaining significant improvement. One month after disease onset, the patient received efgartigimod (10 mg/kg intravenously) weekly for four doses.
Results
We report the results of this treatment on muscle strength, patient disability, and nerve conduction studies. The tolerability profile was satisfactory, and the patient was able to walk alone after 4 months from disease onset.
Interpretation
The potential role of efgartigmod in GBS should be explored in future clinical trials.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neurology, Neurocenter of Southern Switzerland EOC, Ospedale Regionale di Lugano, Lugano, Switzerland.
- Faculty of Biomedical Sciences, Università della Svizzera Italiana, Lugano, Switzerland.
- Clinica Hildebrand Centro di riabilitazione, Brissago, Switzerland.
- Intensive Care Unit, Department of Intensive Care, Lugano, Switzerland.
ORCID-Profile: P Ripellino, C Gobbi
Förderung
- Fondazione Balli
Zitieren
APA
Ripellino, P., Dinacci, D., Conti, M., Galli, G., Frediani, L., Rossi, P., & Gobbi, C. (2025). Efgartigimod as Add‐On Treatment in Refractory Guillain–Barré Syndrome: A Case Report. European Journal of Neurology, 32(8). https://doi.org/10.1111/ene.70308
Vancouver
Ripellino P, Dinacci D, Conti M, Galli G, Frediani L, Rossi P, et al. Efgartigimod as Add‐On Treatment in Refractory Guillain–Barré Syndrome: A Case Report. European Journal of Neurology. 2025;32(8). doi:10.1111/ene.70308
BibTeX
@article{Ripellino2025,
author = {Ripellino, P and Dinacci, D and Conti, M and Galli, G and Frediani, L and Rossi, P and Gobbi, C},
title = {Efgartigimod as Add‐On Treatment in Refractory Guillain–Barré Syndrome: A Case Report},
journal = {European Journal of Neurology},
year = {2025},
volume = {32},
number = {8},
doi = {10.1111/ene.70308}
}
EUVIMED